Replies to post #9508 on Aurinia Pharmaceuticals Inc (AUPH)

[Jesspro]

CoolG, have they given any reason why these races with LN are hard to treat? If so, I don’t know the logic of testing more patients from this group. It’s like saying, we improve the trial location but we are treating hard to treat patients from this new location. If this is the case, I would rather use the p2 protocol.

[biotech_researcher]

Cool, it sounds like you are less enthusiastic now? I expect data will be good, so we obtain a pop, but ph 3 results are a relative easy hurdle jump over compared to the approval process over the next 6-9 months. THAT is the real test. I expect many will sell on the data and not risk the idiosyncrasies of the FDA. I’ve already cleaned the sell-sell-sell button on my laptop getting ready as I’m dumping on the day of the data release. I expect many will do this as well and it will cap the gain that Aurina will achieve on that day no doubt. We’ll get a pop, but a steady decline after that and not a close at the day’s high.